Brief: Compugen Presents Preliminary Results From Phase 1/2 Dose Escalation Study of COM701 with Opdivo and BMS-986207 at SITC 2021
12/11/2021 12:28
Nov 12 (Reuters) - Compugen Ltd CGEN.TA :
* COMPUGEN PRESENTS PRELIMINARY RESULTS FROM PHASE 1/2 DOSE
ESCALATION STUDY OF COM701 WITH OPDIVO® AND BMS-986207
(ANTI-TIGIT ANTIBODY) AT SITC 2021
* COMPUGEN LTD - EXPANSION COHORTS ENROLLING IN SELECT
BIOMARKER-INFORMED TUMOR TYPES
* COMPUGEN LTD - TRIPLE COMBINATION OF COM701, NIVOLUMAB AND
BMS-986207 (ANTI-TIGIT ANTIBODY) WAS WELL TOLERATED
* COMPUGEN LTD - BEST RESPONSE OF STABLE DISEASE IN HEAVILY
PRETREATED HETEROGENOUS ALL-COMER PATIENT POPULATION WITH A
MEDIAN OF 10 AND UP TO 19 PRIOR THERAPIES
Source text for Eikon: ID:nPn8dh09ta
Further company coverage: CGEN.TA
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Compugen
See all newsIsrael's Compugen Q2 revenue more than doubles, net loss narrows
Brief: Compugen Announces The Appointment Of Michele Holcomb, Ph.D., To Its Board Of Directors
Brief: Compugen Monetizes Portion Of Rilvegostomig Future Royalties To Astrazeneca For Up To $90 Million
Brief: Compugen Announces First Patient Dosed In Com701 Global Platform Trial In Platinum Sensitive Ovarian Cancer
Brief: Compugen Announces Leadership Transitions Effective September 2025